Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older

Cancer Control

Volumn 14, Issue 1, 2007, Pages 63-68

  Balasubramanian, Bijal A ^a   Gandhi, Sampada K ^b   Demissie, Kitaw ^b,d   August, David A ^d,e   Kohler, Betsy ^f   Osinubi, Omowunmi Y ^c   Rhoads, George G ^b,d  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^c The State University of New Jersey   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CONTROLLED STUDY; ELDERLY CARE; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; UNITED STATES;

EID: 33846508060     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480701400109     Document Type: Article

References (23)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339:71-85.
2. Adjuvant Therapy for Breast Cancer. National Institutes of Health Consensus Development Conference Statement. November 1-3, 2000. Available at http://consensus.nih.gov/cons/114/114_intro.htm. Accessed November 12, 2006.
3. Cascinu S, Del Ferro E, Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol. 1996;19:371-374.
4. Lash TL, Silliman RA, Guadagnoli E, et al. The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer. 2000;89:1739-1747.
5. Du XL, Key CR, Osborne C, et al. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138:90-97.
6. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
7. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
8. de la Haba Rodriguez JR, Mendez Vidal MJ, Gomez Espana A, et al. Adjuvant treatment in elderly patients with breast cancer: critical review of clinical practice. Am J Clin Oncol. 2003;26:398-401.
9. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19:1455-1461.
10. Guadagnoli E, Shapiro C, Gurwitz JH, et al. Age-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer. J Clin Oncol. 1997;15:2338-2344.
11. Mandelblatt JS, Hadley J, Kerner JF, et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer. 2000;89:561-573.
12. Merchant TE, McCormick B, Yahalom J, et al. The influence of older age on breast cancer treatment decisions and outcome. Int J Radiat Oncol Biol Phys. 1996;34:565-570.
13. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983;1:257-261.
14. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet. 1985;1:836-840.
15. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. 1987;2:171-175.
16. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. "Nolvadex" Adjuvant Trial Organisation. Br J Cancer. 1988;57:608-611.
17. Delozier T, Spielmann M, Mace-Lesec'h J, et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Federation Nationale des Centres de Lutte Contre le Cancer Breast Group. J Clin Oncol. 2000;18:3507-3512.
18. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
19. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
20. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125-130.
21. Smith RE, Good BC. Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others. Endocr Relat Cancer. 2003;10:347-357.
22. Elwood JM, Godolphin W. Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer. 1980;42:635-644.
23. Mandala M, Moro C, Ferretti G, et al. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. Anticancer Res. 2001;21:585-588.